Demographics | |
Mean age (years) | 50 ± 12 (20–77) |
Male sex | 74 % (88) |
HCV genotype | |
1a | 20 % (23) |
1b | 44 % (53) |
2 | 12 % (14) |
3 | 20 % (24) |
4 | 4 % (5) |
Mean HCV-RNA (10E6 IU ml-1) | 3.23 ± 6.61 (0.02–34.50) |
Cirrhosis | 46 % (55) |
Treatment history | |
Treatment naive | 50 % (59) |
Treatment experienced | 50 % (60) |
Protease inhibitor experienced | 23 % (27) |
Clinical chemistry | |
Platelets (10E3 μl-1) | 155 ± 74 (13–396) |
Total bilirubin (mg dl-1) | 1.0 ± 0.8 (0.2–4.7) |
INR | 1.09 ± 0.25 (0.84–2.65) |
Creatinine (mg dl-1) | 0.78 ± 0.21 (0.43–1.85) |